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ABSTRACT
Purpose: Though the efficacy of MEK inhibitors is being investigated in KRAS-
mutant colorectal cancers (CRC), early clinical trials of MEK inhibitor monotherapy 
did not reveal significant antitumor activity. Resistance to MEK inhibitor monotherapy 
developed through a variety of mechanisms converging in ERK reactivation. Since ERK 
increases cyclin D expression and increases entry into the cell cycle, we hypothesized 
that the combination of MEK inhibitors and CDK4/6 inhibitors would have synergistic 
antitumor activity and cause tumor regression in vivo.
Results: The combination of MEK and CDK4/6 inhibitors synergistically inhibited 
cancer cell growth in vitro and caused tumor regression in vivo in cell line and 
patient-derived xenograft models. Combination therapy markedly decreased levels 
of phosphorylated ribosomal protein S6 both in vitro and in vivo and decreased Ki67 
staining in vivo.
Experimental Design: We performed in vitro proliferation, colony formation, 
apoptosis, and senescence assays, and Western blots, on a panel of 11 KRAS mutant 
CRC cell lines treated with the MEK inhibitor MEK162, the CDK4/6 inhibitor palbociclib, 
or the combination. We also treated 4 KRAS mutant CRC cell line and patient-derived 
xenografts with the MEK inhibitor trametinib, the CDK4/6 inhibitor palbociclib, or the 
combination, and performed immunohistochemical and reverse phase protein array 
analysis.
Conclusions: Combined inhibition of both MEK and CDK4/6 is effective in 
preclinical models of KRAS mutant CRC and justifies a planned phase II clinical trial 
in patients with refractory KRAS-mutant CRC.
Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in 
KRAS mutant colorectal cancer models.
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INTRODUCTION
Somatic activating mutations in KRAS or NRAS 
are present in up to 52% of colorectal cancer (CRC) 
[1, 2], causing constitutive activation of the RAF/
MEK/ERK signaling pathway independent of upstream 
receptor tyrosine kinases like the epidermal growth 
factor receptor (EGFR). These mutations are known 
predictive biomarkers of resistance in metastatic CRC to 
anti-EGFR therapy, such as cetuximab or panitumumab, 
and consequently patients whose tumors harbor KRAS or 
NRAS mutations have fewer therapeutic options. There are 
currently no known effective therapies that exploit KRAS 
or NRAS mutations to target malignant cells.
Though MEK inhibitors were found to have 
intriguing in vitro activity in KRAS mutated CRC models 
[3–6], efficacy was variable in different cell lines. More 
importantly, MEK inhibitor monotherapy proved to be 
largely ineffective in patient-derived xenograft (PDX) 
murine models [7] and in human clinical trials [8]. Myriad 
mechanisms of resistance have been identified [9–13], 
with most causing increased signaling through upstream 
receptor tyrosine kinases or activation of parallel signal 
transduction cascades to bypass or overcome MEK 
inhibition and reactivate ERK signaling. Indeed, unless 
an approximately ten-fold reduction in ERK activation is 
achieved, cell proliferation persists [14]. Consequently, 
rational drug combinations with MEK inhibitors, 
potentially with agents that target downstream effectors 
of ERK, are likely necessary to overcome compensatory 
responses to MEK inhibitors.
Phosphorylation and activation of ERK is well-
known to cause increased proliferation and increased 
activity of the cell cycle by causing increased cyclin 
D expression [15, 16]. Cyclin D expression is the rate-
limiting step in cell cycle progression from G1 into S 
phase [17]. Cyclin D complexes with and activates cyclin 
dependent kinase (CDK) 4 and 6, which phosphorylate 
and inactivate the tumor suppressor retinoblastoma protein 
(Rb) [18]. In its unphosphorylated state, Rb is bound to 
the transcription factor E2F, and Rb phosphorylation 
releases E2F, freeing it to increase transcription of genes 
promoting cell cycle progression into S phase. Selective 
CDK4/6 inhibitors have been developed with minimal 
off-target kinase inhibition [19–21], with the caveat 
that they require intact expression of Rb for antitumor 
efficacy [19]. However, inactivating mutations in RB1 are 
very uncommon in CRC and do not exceed the expected 
background rate of mutations [1], and in fact the majority 
of CRCs have higher levels of Rb than normal colon 
mucosa [22]. Furthermore, loss of Rb speeds cell growth 
in conjunction with RAS mutations [23–25], indicating 
that RAS mutant cell growth increases with unimpeded, 
dysregulated cell cycle progression. Thus, RAS mutant 
CRCs are a candidate for further investigation of the 
efficacy of CDK4/6 inhibitors.The combination of CDK4/6 
and MEK inhibitors may be particularly efficacious in 
RAS mutated malignancies. Inhibition of CDK4 was 
found to be synthetically lethal in vitro and in vivo 
in KRAS mutant non-small cell lung cancers [26, 27]. 
However, CDK4/6 inhibitor monotherapy in early human 
clinical trials did not yield any responses in CRC [28–
31], arguing that combination therapy is required. In an 
inducible NRAS Q61K genetically engineered mouse 
model of melanoma, the combination of MEK and 
CDK4/6 inhibitors caused tumor regression that paralleled 
extinction of mutant NRAS, but either monotherapy alone 
did not [32]. Consequently, we hypothesized that the 
combination of a CDK4/6 inhibitor and a MEK inhibitor 
would have synergistic antitumor activity in vitro and in 
vivo in KRAS mutant CRC.
RESULTS
Dual inhibition of MEK and CDK4/6 markedly 
attenuates cell growth in vitro
To examine the efficacy of dual blockade of CDK4/6 
and MEK on KRAS mutant CRC cells, cell growth and 
colony formation were determined after treatment with 
the MEK inhibitor MEK162 and the CDK4/6 inhibitor 
palbociclib, using clinically relevant doses of palbociclib 
[28, 29] and doses optimized to each cell line to maximally 
display contrast of cell growth between monotherapies and 
combination therapy (See Supplementary Table S1 and 
Figure S1). As shown in Figure 1A–1G, the combination 
of MEK162 and palbociclib was markedly effective in 
attenuating cell growth and colony formation in a broad 
panel of KRAS mutant CRC cell lines. As shown in 
Figure 1H, the combination of MEK inhibitor and CDK4/6 
inhibitor was more effective in limiting colony formation 
and cell growth than MEK inhibitor monotherapy in the 
majority of the 11 KRAS mutant CRC cell lines assayed. 
Dual inhibition of MEK and CDK4/6 
synergistically inhibits growth of KRAS mutant 
colon cancer cell lines
To examine the mechanism of dual blockade of 
CDK4/6 and MEK on KRAS mutant CRC cells, cell 
growth was assessed with MTS assay after treatment 
with MEK162 and palbociclib for 72 hours. The cell 
lines HCT116, Lovo, SW480, and LS174T showed 
improved efficacy of the combination of MEK162 
and palbociclib compared to either monotherapy, 
with the effect reaching significance for Lovo, 
SW480, and LS174T at all concentration levels tested 
(Figure 2A–2D). On assessment for formal synergy, 
these three cell lines all displayed synergistic effects 
(combination index, CI, at EC50 for Lovo was 0.05, for 
SW480 was 0.68, and for LS174T was 0.22; CI values 
< 1 indicate synergy). An isobologram for these findings 
is depicted in Figure 2E. 
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Using a flow-based annexin V-FITC assay, treatment 
with the combination of CDK4/6 inhibitor and MEK 
inhibitor for 72 hours induced apoptosis in a greater 
proportion of cells than either monotherapy in HCT116 
and Lovo cell lines, but not in SW480 and SW403 
(Figure 3A–3B; SW403 not shown). The combination also 
induced senescence in a greater proportion of cells after 
72 hours as determined by staining for senescence-associated 
beta-galactosidase, for Lovo and SW480 (Figure 3D–
3E), while there was negligible staining in HCT116 cells 
regardless of treatment (not shown), and SW403 could not 
be assessed because of cell clumping precluding accurate 
counting. Overall, these results suggest that the synergy of 
the drug combination acts through some combination of 
increased apoptosis and/or senescence, at least in vitro.
Dual inhibition of MEK and CDK4/6 results 
in greater inhibition of phosphorylation of 
ribosomal protein S6
To determine mechanisms of action and inform on 
pharmacodynamic markers of response, we performed 
reverse phase protein arrays (RPPA) using protein 
lysates obtained from 10 KRAS mutant CRC cell lines 
treated for 24 hours with MEK162, palbociclib, the 
combination, or DMSO control (Figure 4A–4B). Protein 
changes after MEK inhibitor treatment were in line with 
previous publications using RPPA [32, 33], including 
downregulation of Myc and Fra1, upregulation of Bim, 
and a feedback increase in MEK phosphorylation. 
Consistent with the selectivity of palbociclib for 
CDK4/6, only five proteins were consistently affected 
by palbociclib across all lines, including significant 
downregulation of the proliferation markers Rb, 
Foxm1, Plk1, and Ccnb1 (Cyclin B1). Palbociclib was 
consistently better than or at least as efficient as MEK162 
in suppressing these markers. Importantly, the drug 
combination more strongly downregulated these markers 
than either monotherapy alone in every cell line tested, 
Figure 4B suggesting a cooperative antiproliferative effect. 
Unexpectedly, palbociclib alone also resulted in the 
inhibition of phosphorylation of ribosomal protein S6 in 
8 of the 10 lines, which has not been reported previously. 
MEK162 alone also downregulated pS6, consistent with 
Figure 1: Combination of MEK and CDK4/6 inhibitors markedly attenuates cell growth in vitro in a panel of KRAS 
mutant CRC cell lines. (A–F), Colony assays for six representative cell lines treated with the CDK4/6 inhibitor palbociclib (PD), 
the MEK inhibitor MEK162 (MEK), the combination (MEK/PD), or with DMSO control for 10–14 days. Results are normalized to 
MEK162 monotherapy. The data represent mean values ± SD for 3–4 independent experiments. (G), Depiction of the stained cell wells. 
(H), Summary colony assay results for a panel of 11 KRAS mutant CRC cell lines treated with DMSO control, PD, MEK, or MEK/PD at 
concentrations approximating the IC50 for MEK monotherapy for 10–14 days. Results here are normalized to DMSO control. A waterfall 
plot is depicted showing values, with cell lines consistently depicted in the same order of T84, LS174T, SW1116, SW948, LS1034, 
HCT116, SW837, SW403, SW480, Lovo, and SKCO1. The data represent mean values for 3–4 independent experiments. *p < 0.05, 
♦p < 0.006. All p-values were generated by Student’s t-test.
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known signaling, and the effect was more marked with 
the drug combination in all cell lines except HCT116. 
These findings were recapitulated by immunoblotting 
for 5 of the lines (Figure 4D) including HCT116. In 
SW480, SKCO1, Lovo, and SW403, pS6 was nearly or 
completely undetectable after combination treatment. 
Notably, pS6 has been identified as a marker of in vivo 
responsiveness to MEK inhibitors in BRAF-mutant 
melanoma [34]. Thus, the muted combination effect 
in HCT116 on pS6 is consistent with the observed lack 
of formal drug synergy (Figure 2A). Furthermore, 
the combination demonstrated slight but significant 
cooperative downregulation in components upstream of 
pS6, including phospho-mTOR, phospho-p70-S6 kinase, 
and p90 ribosomal S6 kinase (p90rsk) (see Figure 4B, 4C). 
These findings together suggest a degree of cross-talk or 
feedback between CDK4/6 signaling and mTOR. 
As S6 also lies downstream of the PI3K pathway, 
we next asked whether activation of PI3K by PIK3CA 
mutations affected the pS6 response to combination 
therapy. We noted that of three PIK3CA mutant 
cell lines, HCT116 and SW948 had relatively less 
pS6 downregulation than PIK3CA wild-type cell lines, 
but that the third, LS174T, had strong pS6 downregulation 
(see Figure S2). Consequently, though PIK3CA mutation 
may be associated with shallower changes to phospho-S6 
on treatment, it may not be completely sufficient or fully 
penetrant in blocking pS6 downregulation. 
Dual inhibition of MEK and CDK4/6 inhibits 
tumor growth in vivo in KRAS mutant CRC cell 
line xenograft and PDX
We next tested the combination in vivo using 
CRC xenograft models. The combination of the MEK 
and CDK4/6 inhibitors trametinib (3 mg/kg QOD) and 
palbociclib (100 mg/kg QD) using oral gavage yielded 
significantly greater tumor growth inhibition in murine 
xenografts of the KRAS mutant Lovo cell line compared 
to vehicle-treated controls or treatment with monotherapy 
of each drug alone (see Figure 5A). The combination 
treatment did cause weight loss in mice, with a maximum 
weight loss tending to occur at days 10 through 14. 
Importantly though, mice with less weight lost showed 
weight stabilization and/or complete recovery with 
continued treatment (see Figure S3A), suggesting that 
alternative dosing schedules may improve toxicity. We 
also developed a trametinib/palbociclib chow calculated 
to deliver a similar dose to oral gavage continuously. Lovo 
xenografts again showed regression upon treatment with 
this combination chow, demonstrating similar efficacy 
to oral gavage (see Figure S3B). Independent cell line 
Figure 2: Combination of MEK and CDK4/6 inhibitors synergistically attenuates cell growth in a panel of KRAS 
mutant CRC cell lines. (A), HCT116 cells were treated with the CDK4/6 inhibitor palbociclib (PD) (400 nM, 200 nM, 100 nM, or 50 nM) 
and/or the MEK inhibitor MEK162 (MEK) (200 nM, 100 nM, 50 nM, or 25 nM respectively) or control for 72 hours and proliferation and 
cell growth was assessed using MTS assay. The data represent mean values ± SD for 3 independent experiments. (B), Lovo cells treated 
as described for HCT116. (C), SW480 cells treated as described for HCT116. (D), LS174T cells treated as described for HCT116. (E), 
Isobologram shows synergy of the combination of PD0332991 and MEK162. Plotted points farther to the bottom left of the Figure represent 
increasing degree of synergy. *p < 0.05, ♦p < 0.006. All p-values were generated by Student’s t-test.
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xenografts of HCT116 and SW480 also showed tumor 
regression in mice treated with the combination chow 
(see Figure 5B–5C). No tumors showed resistance to 
the combination at 30+ days of treatment. Furthermore, 
these mice did not demonstrate weight loss exceeding 
20% or morbidity with the combination chow despite 
demonstrating tumor shrinkage.
We also leveraged a KRAS mutant CRC PDX model 
that we have recently established. Similar to the results 
in the Lovo cell line xenograft model, the combination of 
MEK and CDK4/6 inhibitors yielded significantly greater 
tumor growth inhibition in the PDX model compared to 
vehicle-treated controls or treatment with monotherapy 
of each drug alone (see Figure 5D). Notably, this PDX 
model responded to the combination despite harboring an 
atypical KRAS A146T mutation and an activating AKT1 
E17K mutation. The combination treatment yielded 
regression of tumors after 21 days, unlike treatment with 
either monotherapy. The combination treatment again 
caused weight loss in mice, with a nadir weight between 
days 7 and 14 before stabilization and partial recovery of 
the lost weight (see Figure S3C).
To molecularly compare the in vivo inhibition with 
our earlier in vitro studies, RPPA was performed using 
protein lysates obtained from PDX tumors after treatment 
for 21 days (Figure 6A–6B). Similar to the in vitro data, 
treatment with the combination of MEK and CDK4/6 
inhibitors downregulated Rb, Plk1, Ccnb1, and pS6 to a 
greater extent than either monotherapy alone. Interestingly, 
unlike in the in vitro model, treatment with trametinib did 
Figure 3: Combination of MEK and CDK4/6 inhibitors inhibits cell growth in KRAS mutant CRC cell lines through 
a variety of mechanisms. (A), HCT116 cells were treated with the CDK4/6 inhibitor palbociclib (PD, 400 nM), the MEK inhibitor 
MEK162 (MEK, 200 nM), the combination (MEK/PD), or with DMSO control for 72 hours, and stained with propidium iodide and annexin 
V-FITC prior to performing flow cytometry. The data represent mean values ± SD for 3 independent experiments. (B), Lovo cells were 
treated as described for HCT116. C, SW480 cells were treated as described for HCT116. *p < 0.05. ♦p < 0.01 for (A–C), with all p-values 
generated by Student’s t-test. (D), Lovo cells were treated with PD (400 nM), MEK (200 nM), the combination, or with DMSO control 
for 72 hours, and stained with X-gal to detect senescence-associated β-galactosidase. The proportion of stained cells in 10 random high-
powered fields was counted. The data shows mean values from a representative experiment ± SD for the 10 fields. (E), SW480 cells were 
treated as described for Lovo. ♦p ≤ 0.0002 for combination compared to any other value, with all p-values generated by Student’s t-test.
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not show a feedback increase in phosphorylation of MEK 
(see Figure 6B) after 21 days of treatment. Additionally, 
a number of proteins showed cooperative changes upon 
combination therapy that were not observed in vitro 
including CDK1 and FASN, suggesting the influence of 
the tumor microenvironment on inhibitor-induced protein 
changes. Immunohistochemical staining from PDX 
samples demonstrated a marked decrease in cell staining 
for Ki67 after 21 days of treatment (see Figure 6C–6D). 
Staining for phospho-S6 was decreased in the trametinib 
and the combination trametinib + palbociclib treated 
groups compared to control in this chronically-treated 
cohort (see Figure S4). Collectively, these data support 
the hypothesis that the combination of MEK and CDK4/6 
inhibitors induces tumor regression via the cooperative 
induction of cell cycle arrest, and that Ki67 and pS6 may 
serve as surrogates for combined target engagement.
DISCUSSION
Though mutations in KRAS and other RAS 
isoforms are widespread in many malignancies, as yet 
efforts to therapeutically target KRAS mutations have 
been unsuccessful. Previous studies investigating the 
use of MEK inhibitor monotherapy revealed that though 
resistance may arise through a variety of mechanisms, 
generally they result in compensatory activation of 
parallel signaling pathways to reactivate phosphorylation 
of ERK [9–13]. ERK plays a key role in promoting cell 
cycle progression and proliferation [35], including through 
increased transcription of cyclin D1 [15, 16]. Several 
synthetic lethality screens have been performed on KRAS 
mutant cancer cell lines to determine potential targets, 
and results have frequently included genes important in 
cell cycle progression or mitosis, such as CDK1 [36], 
cyclin A2 [37], PLK1 [37], and CDC6 [38]. Furthermore, 
abrogation of CDK4 was synthetically lethal in KRAS 
mutant non-small cell lung cancer models [26, 27]. 
Consequently, we hypothesized that the combination of 
inhibition of the MAPK pathway with a MEK inhibitor 
and inhibition of cell cycle progression with a CDK4/6 
inhibitor would be more effective. Indeed, our studies 
demonstrate that combined inhibition of MEK and 
CKD4/6 is synergistic in vitro in a variety of KRAS mutant 
CRC cell lines and yields tumor regression in vivo in cell 
line xenografts and PDXs of KRAS mutant CRC.
It was previously not well recognized that CDK4/6 
inhibition would inhibit phosphorylation of S6, which is 
Figure 4: Combination of CDK4/6 and MEK inhibitors induces greater inhibition of phosphorylation of S6 and other 
growth factor signaling and cell cycle proteins. (A), Protein lysates were obtained from a panel of 9 KRAS mutant CRC cell lines 
after treatment with DMSO control, palbociclib (PD) 400 nM, MEK162 (MEK) 200 nM, or MEK162 200 nM + palbociclib 400 nM (MEK/
PD) for 24 hours, and RPPA was performed. Protein levels were normalized to DMSO controls of each cell line, and a log2 heatmap of 
the most differentially expressed proteins was generated. (B), Median expression levels of proteins in KRAS mutant CRC cell lines treated 
with MEK162 (MEK) alone, palbociclib (PD) alone, or the combination (MEK/PD), relative to DMSO-treated control. p-values were 
determined using paired Student’s t-test. (C), Protein expression data from RPPA was mapped according to relevant pathways. Circles 
represent phosphorylated epitopes on the proteins and squares represent total proteins. Activating KRAS mutations are thought to lead to 
constitutive activation of downstream signaling pathways, but adding MEK inhibitor and CDK4/6 inhibitor yielded the depicted changes 
in protein expression. (D), Western blotting of the indicated antibodies for KRAS mutant cell lines HCT116, SW480, SKCO1, Lovo, and 
SW403 treated with palbociclib 400 nM and/or MEK162 200 nM for 24 hours.
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more typically associated with growth factor signaling 
through the PI3K/MTOR and MEK/ERK pathways. 
Our results have most notably found that both inhibition 
of MEK and CDK4/6 individually cause decreases in 
phospho-S6 levels, and the combination yields even 
greater decrease. Ribosomal protein S6 is a component of 
the 40S ribosomal subunit that can be phosphorylated at 
five serine residues by S6 kinase in the mTOR pathway 
or by p90rsk in an ERK-dependent manner [39–41]. 
Phosphorylated S6 is associated with increased cell size 
and increased translation of polypeptides encoded by 
mRNAs with a 5′-polypyrimidine tract [41]. Entry into the 
cell cycle is associated with increased phosphorylation of 
S6 at Ser240/244 [42], and so decrease in phospho-S6 may 
reflect generally decreased flux through the cell cycle. 
Nevertheless, decreased phospho-S6 level upon 
combination treatment appears to be a pharmacodynamic 
biomarker of therapy that warrants further evaluation. 
Mechanisms of action of CDK4/6 inhibitors also 
remain under investigation. Decreases in the levels of 
cyclin B1, FOXM1, and PLK1 were observed with the 
combination of CDK4/6 inhibitors and MEK inhibitors. 
Similar changes in levels of downstream target genes have 
been found in vitro in estrogen receptor-positive breast 
cancer cell lines treated with palbociclib combined with 
the aromatase inhibitor letrozole [43]. Decreases of these 
effectors are important in mediating cellular fate. CDK4 
and CDK6 phosphorylate and stabilize the transcription 
factor FOXM1 to maintain G1/S phase gene expression 
and suppress senescence [44], so decreased levels of 
FOXM1 likely contribute toward shifting the cell into 
senescence. PLK1 is a kinase important in promoting 
mitotic entry and proliferation [45], and its transcription 
is upregulated by E2F [46], and thus decreased levels of 
PLK1 are expected with decreased phospho-RB. Cyclin 
B1 complexes with CDK1 to promote mitotic entry, and 
accumulation of cyclin B1 depends on E2F target genes 
[47], so decrease in phospho-RB levels would also likely 
result in decreased cyclin B1 levels. 
A previous study of palbociclib in KRAS mutant 
pancreatic cancer cell lines showed concern that though 
palbociclib monotherapy inhibited cell proliferation, 
it appeared to also increase epithelial mesenchymal 
transition (EMT) in cell lines with wild-type SMAD4 
[48]. In that study, CDK4/6 inhibition or knockdown 
resulted in induction of the EMT markers beta-catenin, 
Slug, N-cadherin, and vimentin. However, in our 
experiments with both KRAS mutant CRC cell lines and 
KRAS mutant PDX, there were no significant changes 
in protein levels of E-cadherin, N-cadherin, or beta-
catenin in vitro or in vivo. Notably, in vivo results were 
obtained after 21 days of treatment. Several of the cell 
lines used, including HCT116 and Lovo, were wild-type 
in SMAD4 [49], as was the PDX tested. In vitro, there 
were also no differences in vimentin or fibronectin. There 
was a trend toward increased fibronectin level in vivo 
Figure 5: Combination of CDK4/6 and MEK inhibitors induces tumor regression in vivo in KRAS mutant CRC 
xenografts. (A), Lovo cell line xenografts were treated with vehicle control daily, palbociclib 100 mg/kg daily, trametinib 3 mg/kg every 
2 days, or palbociclib 100 mg/kg daily + trametinib 3 mg/kg every 2 days, and tumor volume was measured twice per week. Data are mean 
± SEM, with 10 mice/arm. *p < 0.01 on day 21 for combination vs. each other arm by Student’s t-test. (B), HCT116 cell line xenografts 
were treated with control chow or chow containing trametinib + palbociclib, and tumor volume was measured longitudinally. ♦p < 0.001 
on day 7 by Student’s t-test. (C), SW480 cell line xenografts were treated with control chow or chow containing trametinib + palbociclib, 
and tumor volume was measured longitudinally. ♦p < 0.001 on day 20 by Student’s t-test. (D), Xenografts implanted with patient-derived 
CRC cells harboring KRAS A146T mutation were treated with vehicle control daily, palbociclib 100 mg/kg daily, trametinib 3 mg/kg 
every 2 days, or palbociclib 100 mg/kg daily + trametinib 3 mg/kg every 2 days, and tumor volume was measured twice per week. Data 
are mean ± SEM, with 9–10 mice/arm. ♦p < 0.001 on day 21 for combination vs. any other arm by Student’s t-test. Dotted lines represent 
50% decrease in tumor volume. (E), Change in tumor volume for each of the patient-derived xenograft mice in D at day 21 of treatment.
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with combination MEK and CDK4/6 inhibitors that was 
not observed with CDK4/6 inhibitor monotherapy. This 
result may be different than the in vitro result due to the 
longer duration of treatment in the in vivo experiment or 
due to stromal cells increasing fibronectin expression. 
While increased fibronectin is commonly associated with 
EMT, fibronectin levels may also be altered due to other 
phenomena, and increased fibronectin expression has even 
been associated with increased cell senescence [50], so 
elevated fibronectin in isolation is not sufficient to state 
there is an increase in EMT. Indeed, inhibition of CDK4 
in a triple-negative breast cancer cell line caused decreases 
in the EMT-associated transcription factors Snail and 
Twist and decreases in phosphorylated Smad3 [51, 52]. 
Thus, differences in EMT or other feedback pathways in 
response to CDK4/6 inhibition are likely to be cell-type-
specific, but warrant further investigation.
Though the combination of CDK4/6 inhibitors 
and MEK inhibitors has previously been found to be 
effective in NRAS-mutant melanoma models [32], 
we felt that empirically assessing the efficacy of the 
combination in KRAS-mutant CRC models was necessary 
to justify consideration of clinical trials in patients with 
CRC, especially given the many distinctions between 
RAS-mutated melanomas and CRCs. First, RAS-
mutated melanoma is predominantly NRAS-mutated at 
codon 61, while RAS-mutated CRC is predominantly 
KRAS-mutated at codons 12 and 13. NRAS and KRAS 
mutations have distinct phenotypic effects on resulting 
tumors in CRC genetically engineered mouse models 
[53], and mutations at different codons even within 
NRAS cause different phenotypes [54]. Second, RAS-
mutant melanoma and CRC have markedly different 
patterns of concomitant genomic alterations, such as 
Figure 6: Combination of CDK4/6 and MEK inhibitors induces greater inhibition of phosphorylation of S6 and other 
growth factor signaling and cell cycle proteins in vivo in PDX models of KRAS mutant CRC. (A), Protein lysates were 
obtained from tumors after 21 days of treatment with vehicle control (C), trametinib (MEK), palbociclib (PD), or trametinib + palbociclib 
(MEK/PD), and RPPA was performed. Protein levels were normalized to the geometric mean of vehicle-treated controls, and a heatmap of 
the most differentially expressed proteins was generated. Values are log2-transformed fold-change compared to the geometric mean of the 
controls. (B), Median expression levels of selected proteins in KRAS mutant CRC PDXs treated with trametinib (MEK) alone, palbociclib 
(PD) alone, or the combination (MEK/PD) for 21 days, relative to vehicle-treated control. p-values were determined using paired Student’s 
t-test. (C), Percentage of nuclear area stained by Ki67 antibody. Data represent mean ± SD of samples from 3–4 mice. *p ≤ 0.02, ♦p < 0.003 
by Student’s t-test. (D), Representative immunohistochemistry images for Ki67 staining.
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CDKN2A loss [55, 56], which are likely to be associated 
with sensitivity to CDK4/6 inhibitors [57]. Third, MEK 
inhibitor monotherapy is more effective in clinical trials 
of NRAS-mutant melanoma than in KRAS-mutant CRC, 
as early phase III trial data of MEK162 (binimetinib) 
in NRAS-mutant melanoma showed the study met its 
primary endpoint of improvement in progression-free 
survival (unpublished data), while MEK inhibitors had 
no evidence of efficacy in phase I studies in RAS-mutant 
CRCs [58]. Finally, the tissue-specific context of oncogene 
mutations is clearly critical in determining sensitivity to 
targeted therapies; notably, single-agent BRAF inhibitors 
or combination of BRAF and MEK inhibitors are effective 
in BRAF-mutant melanomas [59, 60], while they are not 
effective in BRAF-mutant CRCs [61, 62]. Given these 
concerns, our data demonstrated preclinical efficacy of 
combination MEK and CDK4/6 inhibitors in RAS-mutant 
CRCs. This data also complements the recent report of 
the combination of palbociclib and trametinib in KRAS-
mutant CRC PDX models [63], but demonstrates that 
inhibition of phospho-S6 is a potential pharmacodynamic 
biomarker, and uniquely demonstrates that this inhibition 
is synergistic with the combination of CDK4/6 and MEK 
inhibitors in a broader number and mutational diversity 
of cell lines, including “atypical” KRAS A146T mutant 
CRC PDX models. Our data has justified development 
of a planned phase II clinical trial of the combination in 
patients with refractory metastatic RAS-mutant CRC. 
In summary, we evaluated a novel combination 
of MEK and CDK4/6 inhibitors in KRAS mutant CRCs 
and found synergistic inhibition of cell growth in vitro, 
with contributions of decreased proliferation, increased 
apoptosis, and increased senescence; and we subsequently 
found the combination of MEK and CDK4/6 inhibitors 
caused tumor regression in vivo in cell line and patient-
derived xenografts. We also described inhibition of 
phosphorylation of ribosomal protein S6 to a greater 
extent with the combination of MEK and CDK4/6 
inhibitors compared to either alone. Though our studies 
were focused on KRAS mutant CRC, this does not rule 
out activity in RAS wild-type or BRAF mutant CRC, and 
further study is warranted. Given the more limited number 
of options in treatment of KRAS mutant CRC compared 
to KRAS wild-type CRC, the development of effective 
therapies for this patient population is an area of unmet 
need. Combinatorial approaches targeting both the MAPK 
pathway and cell cycle regulatory pathways merit further 
preclinical and clinical investigation.
MATERIALS AND METHODS
Cell culture and drugs
A panel of KRAS mutant CRC cell lines was 
cultured in 1:1 DMEM/Ham’s F12 media with 10% 
fetal bovine serum, 1% penicillin/streptomycin, and 
2 mM L-glutamine. Palbociclib/PD0332991 (Selleck 
Chemicals) and MEK162 (Selleck Chemicals) were 
dissolved in dimethyl sulfoxide (DMSO) as 10 mM and 
30 mM stocks, respectively. Lovo cells were obtained 
from ATCC. HCT116, SW480, SKCO1, SW403, SW837, 
LS174T, SW948, SW1116, LS1034, and T84 cell identity 
was verified by short tandem repeat (STR) analysis.
Cell proliferation and colony formation assays
Cells were seeded in a 96-well plate at 2000–
6000 cells/well, incubated overnight at 37°C to allow 
adhesion, and then treated with inhibitors for 72 hours. 
Cell proliferation was determined using MTS solution 
(Promega), and formal assessment for synergy performed 
per the Chou-Talalay method [64, 65] using CompuSyn 
(ComboSyn, Inc, Paramus, NJ). For colony formation 
assay, cells were seeded in a 6-well plate at 8000–
80,000 cells/well, incubated overnight at 37°C to allow 
adhesion, and then treated with inhibitors for 2–3 weeks. 
Cell colonies were fixed with ice-cold methanol and 
stained with 1% crystal violet. The density of colonies over 
the plate area was quantified by ImageJ (NIH) [66]. For 
detection of exposed phosphatidylserine residues reflective 
of apoptosis, Annexin V-FITC apoptosis assay kit (BD 
Biosciences) was used. Cells were seeded at 500,000 cells/
well in 6-well plates, incubated overnight at 37°C to allow 
adhesion, and then treated with inhibitors for 72 hours. 
Cells were washed and stained with annexin V-FITC and 
propidium iodide, and flow cytometry was performed 
using the Gallios flow cytometer (Beckman Coulter) and 
analyzed with Kaluza flow analysis software (Beckman 
Coulter). To measure cell senescence, treated cells were 
stained for senescence-associated beta-galactosidase 
(Chemicon). Cells were seeded at 500,000 cells/well 
in 6-well plates, incubated overnight at 37°C to allow 
adhesion, and then treated with inhibitors for 72 hours. 
Cells were washed with PBS, fixed with glutaraldehyde 
and methanol, washed twice more, and then incubated 
overnight in the dark at 37°C under ambient atmospheric 
conditions with X-Gal. Subsequently, cells were washed, 
and 10 high-powered light microscopy images of each 
well were captured, and cells with blue staining were 
manually counted.
Protein analysis
Reverse-phase protein array analysis (RPPA) was 
performed as previously described [67]. Briefly, cells were 
seeded at 500,000 cells/well in 6-well plates, incubated 
overnight at 37°C to allow adhesion, and then treated with 
inhibitors for 24 hours. Cellular proteins were collected 
and denatured by 1% sodium dodecyl sulfate (SDS) 
with β-mercaptoethanol. The ratio of values for each 
treatment within each cell line compared to control was 
determined. To construct a heatmap, these ratios were 
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log2 transformed, and proteins with at least two cell lines 
with at least 1.74-fold increase or decrease of protein 
expression compared to control were filtered. Protein 
values were clustered using Gene Cluster 3.0 [68], and 
heatmap was created using Java Treeview version 1.1.6r4 
(http://jtreeview.sourceforge.net) [69]. 
For immunoblotting, phospho-p42/44 ERK T202/
Y204, p42/44 ERK1/2, phospho-RB Ser780, RB, and 
phospho-S6 Ser235/236 were purchased from Cell 
Signaling Technology (Danvers, MA). Anti-beta-actin was 
obtained from Sigma-Aldrich. Anti-mouse and anti-rabbit 
horseradish peroxidase-linked secondary antibodies were 
obtained from Cell Signaling Technology. 
In vivo murine xenografts
CD-1 nude 6-week old female mice (Charles 
River) were injected with 0.2 ml Lovo cell suspension 
subcutaneously in the right flank and monitored for tumor 
growth. After tumors were established with median tumor 
volume exceeding 100 mm3, treatment of 10 mice/arm was 
commenced via oral gavage with either vehicle control 
per os daily, trametinib 3 mg/kg per os every 2 days, 
palbociclib 100 mg/kg per os daily, or combination of 
trametinib 3 mg/kg per os every 2 days and palbociclib 
100 m/kg per os daily for 21 days. Tumor size and mouse 
weight were measured every 3–4 days. After 21 days, 
treatment was discontinued and mice were sacrificed.
Additionally, immunodeficient female nude 
mice were injected with one million cells of HCT116 
or SW480 subcutaneously in the flank and monitored 
for tumor growth. After tumors were established with 
median tumor volume exceeding 100 mm3, treatment of 
5–8 mice/arm was commenced with chow containing 
combination trametinib and palbociclib or control chow. 
The chow was designed to deliver a dose equivalent to 
0.75 mg/kg trametinib and 75 mg/kg palbociclib. Tumor 
size and mouse weight were measured every 3–5 days. 
Control mice were sacrificed after 11 days due to tumor 
enlargement causing morbidity. After 29–32 days, 
treatment was discontinued and mice were sacrificed.
Patient-derived xenografts
Primary human-tumor xenograft models were 
established as previously described [70]. Tumor specimens 
were obtained from patients with metastatic colorectal 
cancer at the University of Texas MD Anderson Cancer 
Center, and all patients provided informed written consent 
for specimens to be used for research purposes including 
implantation in xenografts. Samples were obtained with 
approval of the institutional review board. Xenografts 
were propagated in NU/J 6-week old female mice 
(Jackson Laboratory). After tumors were established with 
median tumor volume exceeding 300 mm3, treatment of 
10 mice/arm was commenced via oral gavage with either 
vehicle control daily, trametinib 3 mg/kg every 2 days, 
palbociclib 100 mg/kg daily, or combination of trametinib 
3 mg/kg every 2 days and palbociclib 100 m/kg daily for 
21 days. Tumor size and mouse weight were measured 
every 3–4 days. After 21 days, treatment was discontinued 
and mice were sacrificed. Tumors from 3–4 mice per arm 
were excised, segmented, and immediately flash frozen in 
liquid nitrogen. Frozen tumor tissue was homogenized in 
lysis buffer (1% Triton X-100, 50 mM HEPES at pH 7.4, 
150 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 100 mM 
NaF, 10 mM sodium pyrophosphate, 1 mM Na3VO4, 
10% glycerol, protease and phosphatase inhibitors) and 
centrifuged. Protein concentration was determined, and 
lysates were denatured with 4 × SDS sample buffer with 
10% beta-mercaptoethanol, and a final volume of 50 µl 
of 1 µg/µl denature protein lysate was sent for RPPA as 
described above. 
Immunohistochemical stains
Five-micron thick sections were cut and mounted 
from a formalin fixed paraffin-embedded tissue block on 
microscope slides and baked at 60°C for 1 hour. Slides 
were deparaffinized in xylene 3 times for 5 minutes each, 
washed with 100% ethanol 3 times for 5 minutes each, and 
rehydrated in a series of 95%, 70%, 50% ethanol dilutions 
in distilled water for 5 minutes each. Slides were heated in 
10 mM sodium citrate, pH 6.0, with 0.05% Tween-20 in 
a Decloaker chamber (Biocare Medical, Concord, CA) at 
95°C for 30 minutes, then cooled to 90°C for 10 seconds. 
For each stain, slides were washed with 3% H2O2 in 1 × 
TBS for 10 minutes, then in Rodent Block M (Biocare 
Medical) for 20 min, and then with primary antibody for 
30 minutes at room temperature. Primary antibodies were 
rabbit anti-Ki67 (Thermo Scientific) at 1:500 dilution or 
rabbit anti-phospho S6 ribosomal protein (Ser235/236) 
(Cell Signaling) at 1:200 dilution. Afterward, slides 
were incubated with Rabbit-on-Rodent HRP-polymer 
(Biocare Medical) for 25 minutes, stained with DAB for 
5 minutes, and washed with deionized water. Slides were 
counterstained with Harris hematoxylin for 60 seconds 
and washed under water for 1 minute, and then dehydrated 
in 2 changes of 95% ethanol, 3 changes of 100% ethanol, 
and 3 changes of xylene. Images of representative areas of 
the slides were captured. The percentage of nuclear area 
stained for Ki67 was quantitated using the ImmunoRatio 
plugin for ImageJ [71]. The percentage of cells with 
cytoplasmic staining of phospho-S6 was manually 
counted. 
Statistical analyses
Statistical calculations were performed using 
GraphPad Prism version 6.07. Independent samples 
t-tests were used to compare results between two groups. 
Additional details are provided in Figure legends.
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